AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (EGFRExon20Ins) mutations presents a therapeutic challenge.
• Current treatments for EGFRExon20Ins NSCLC, especially brain metastases, have limited efficacy.
• There is a critical need for novel, targeted therapies like tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To evaluate the preclinical efficacy of AZ14289671, a novel TKI, against EGFRExon20Ins mutations in NSCLC.
• To assess the drug's potency, selectivity, and ability to penetrate the blood-brain barrier.
• To determine the potential of AZ14289671 to improve outcomes for NSCLC patients with EGFRExon20Ins.

Main Methods:

• Preclinical assessment using NSCLC cell lines with EGFRExon20Ins mutations.
• Evaluation in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models.
• Assessment of signaling pathway inhibition, tumor regression, and blood-brain barrier penetration.

Main Results:

• AZ14289671 demonstrated potent inhibition of signaling pathways in EGFRExon20Ins models.
• Highly sustained tumor regression was observed across multiple EGFRExon20Ins models.
• The drug showed minimal activity against wild-type (WT) EGFR and successfully crossed the blood-brain barrier.
• Preclinical models showed significant tumor regression and sustained inhibition of signaling pathways.

Conclusions:

• AZ14289671 is a potent, selective, and orally available TKI targeting EGFRExon20Ins mutations.
• Its ability to penetrate the blood-brain barrier offers potential for treating brain metastases in NSCLC.
• AZ14289671 represents a promising therapeutic candidate for NSCLC patients with EGFRExon20Ins mutations.